Careful patient selection and timing for IL-6 (receptor) antagonist treatment in COVID-19 patients is crucial15–17, especially considering the increased risk of side effects—neutropenia, impaired liver function and secondary infections—when IL-6 (receptor) antagonists were used. Here, IL6 is linked to neutropenia.